DEFINITIVE CONTRACT
Active75F40126C00063
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$575.6K
obligated · signed 2 months ago
THE OVERARCHING OBJECTIVE IS TO ESTABLISH A QUANTITATIVE IN VITRO IN VIVO EXTRAPOLATION FRAMEWORK CAPABLE OF PREDICTING THE INFLUENCE OF FORMULATION COMPOSITION, DIGESTION BEHAVIOR, CHYLOMICRON BINDING, AND PRANDIAL STATE ON DRUG BIOAVAILABILITY AND
Performance timeline
Start
Sep 30, 2026
Current end
Dec 29, 2027
Potential end
Dec 29, 2029
with all options
Loading status
Estimated start: Dec 29, 2028
SIMULATIONS PLUS INC
Contract 75F40126C00063
UEI
MZN6WDBMXN24
Parent Company
SIMULATIONS PLUS INC
Capabilities & Certifications
Headquarters Location
Congressional District: 04
Current Obligation
$575,554
Base + Exercised Options
$651,399
Total Ceiling Value
$1,650,102
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC
HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; BASIC RESEARCH
Place of Performance
Congressional District: 08
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.